Core Viewpoint - Green Leaf Pharmaceutical (02186) announced the issuance of exchangeable preferred shares worth $150 million, which will provide immediate cash flow while maintaining strategic flexibility [1] Group 1: Issuance Details - The company has entered into a subscription agreement with a subscriber for the issuance of exchangeable preferred shares, with a total subscription price of $150 million [1] - The exchangeable preferred shares can be converted into shares of Boan Biotechnology according to the terms outlined in the subscription agreement [1] Group 2: Strategic Implications - The board believes that issuing exchangeable preferred shares will allow the company to obtain cash funding immediately while retaining strategic flexibility [1] - The exchange mechanism enables the company to monetize its investment in Boan Biotechnology over a longer period at a price above the current market level, which is expected to yield better results compared to bulk disposals at discounted prices [1] Group 3: Use of Proceeds - The proceeds from the subscription will be used for the general working capital purposes of the group [1] Group 4: Subscriber Information - The subscriber is a company incorporated under the laws of the Cayman Islands and is a wholly-owned subsidiary of RRJ Capital Master Fund IV, L.P., which holds 100% of the issued share capital of the subscriber [1] - The primary business of the subscriber is investment holding activities [1]
绿叶制药(02186)附属拟发行1.5亿美元可交换优先股